Literature DB >> 10652033

Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension.

R Pontremoli1, M Ravera, F Viazzi, C Nicolella, V Berruti, G Leoncini, F Giacopelli, G P Bezante, G Sacchi, R Ravazzolo, G Deferrari.   

Abstract

BACKGROUND: The renin-angiotensin-aldosterone system (RAAS) plays a significant role in the development of hypertensive cardiac and vascular remodeling. Recently, several genetic variants of its key components, which may be clinically relevant and thus prove to be useful in the evaluation of cardiovascular risk, have been described. We therefore investigated the association between ACE I/D, AGT M235T, and AT1 A1266C gene polymorphisms and early signs of target organ damage in 215 untreated patients with essential hypertension (EH).
METHODS: Genotyping was based on the polymerase chain reaction technique, with further restriction analysis when required. Albuminuria was measured as the albumin-to-creatinine ratio (ACR). The left ventricular mass index (LVMI) was assessed by echocardiography (LVH = LVMI > or = 125 g/m2), carotid wall thickness (IMT) by an ultrasonographic (US) scan, and retinal vascular changes by direct ophthalmoscopy (Keith-Wagener classification).
RESULTS: The prevalence of microalbuminuria (Mi), LVH, and retinal vascular changes was 14, 46, and 74%, respectively. ACE, AGT, and AT1 genotype distribution was in agreement with the Hardy-Weinberg equilibrium. There was no difference in age, duration of disease, body mass index (BMI), blood pressure, and lipid profile when data were analyzed on the basis of genotype. Serum levels of angiotensin-converting enzyme (ACE) were related to the ACE genotype (10.2 +/- 0.5, DD; 8.2 +/- 0.3, ID; 6.5 +/- 0.4 IU/mL, II; P < 0. 0001 by analysis of variance). The ACE genotype independently influences serum ACE levels and accounts for approximately 14% of its variations (F = 26.7, r2 = 0.1393, df 1 to 214, P < 0.0001). Patients with DD and ID genotypes showed higher levels of ACR (1.59 +/- 0.2, DD + ID; 0.8 +/- 0.2 mg/mmol, II; P < 0.006 by ANOVA) and bigger LVMI (124.1 +/- 2.3, DD + ID vs. 117.8 +/- 3.6 g/m2, II; P < 0.01 by ANOVA). No differences in the prevalence and degree of target organ damage (TOD) were found when data were analyzed on the basis of the AGT and AT1 genotypes, respectively. Potentially unfavorable combinations of genotypes were also investigated by K-means cluster analysis. Two subgroups of patients were identified (cluster 1, N = 70; cluster 2, N = 57), and each differed significantly with regards to the presence and degree of TOD and patterns of RAAS gene polymorphisms (F, 15.97 for ACR; F, 7.19 for IMT; F, 217.03 for LVMI; F, 3.91 for ACE; F, 4.06 for AGT; and F, 5. 22 for AT1; df 1 to 214, P < 0.02, for each one of the variables examined).
CONCLUSION: The D allele of the ACE gene may be an independent risk factor for the development of target organ damage, and evaluating it could be useful for assessing cardiovascular risk in EH. Unfavorable patterns of RAAS genotypes seem to predispose patients to subclinical cardiovascular disease in EH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652033     DOI: 10.1046/j.1523-1755.2000.00876.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

1.  Variations in angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian populations of different ethnic origins.

Authors:  M A Qadar Pasha; Amjad P Khan; Ratan Kumar; Rekh B Ram; Surinder K Grover; Kaushal K Srivastava; William Selvamurthy; Samir K Brahmachari
Journal:  J Biosci       Date:  2002-02       Impact factor: 1.826

2.  Genetic Determinants of Dyslipidemia in African-Based Populations: A Systematic Review.

Authors:  Jean Jacques Noubiap; Edith Pascale M Mato; Magellan Guewo-Fokeng; Arnaud D Kaze; Houssam Boulenouar; Ambroise Wonkam
Journal:  OMICS       Date:  2018-12

3.  Angiotensin I converting enzyme polymorphism effects in patients with normal pressure hydrocephalus syndrome before and after surgery.

Authors:  Maria del Mar Matarín; Maria Antonia Poca; David Bartrés-Faz; Maria Mataró; Imma C Clemente; Cristina Solé-Padullés; Emili González-Pérez; Pedro Moral; Maite Barrios; Carme Junqué; Juan Sahuquillo
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

4.  Angiotensin II type 1 receptor gene polymorphism and serum angiotensin-converting enzyme level in Egyptian children with systemic lupus erythematosus.

Authors:  Rasha Mohamed Saleh Shoaib; Ayman Hammad; Sohier Yahia; Afaf Elsaid; Camelia Adly Abdel-Malak
Journal:  Clin Rheumatol       Date:  2018-08-09       Impact factor: 2.980

Review 5.  Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness.

Authors:  Guanghong Jia; Annayya R Aroor; Michael A Hill; James R Sowers
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

6.  Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension.

Authors:  Farahnak Assadi
Journal:  Pediatr Cardiol       Date:  2007-02-16       Impact factor: 1.655

7.  Association of the D allele of the angiotensin I converting enzyme polymorphism with malignant vascular injury.

Authors:  N J Mayer; A Forsyth; S Kantachuvesiri; J J Mullins; S Fleming
Journal:  Mol Pathol       Date:  2002-02

8.  Association Between M235T-AGT and I/D-ACE Polymorphisms and Carotid Atheromatosis in Hypertensive Patients: A Cross-Sectional Study.

Authors:  Oana Mocan; Elena Buzdugan; Angela Cozma; Daniel Corneliu Leucuta; Dan Radulescu; Lucia Maria Procopciuc
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

9.  Epidemiology of essential hypertension: the role of genetic polymorphism.

Authors:  V Romano-Spica; M Mettimano; A Ianni; M L Specchia; G Ricciardi; L Savi
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

10.  Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension.

Authors:  Eugenia Espinel; Jose Luis Tovar; Javier Borrellas; Luis Piera; Rosendo Jardi; Francisco Rodriguez Frias; Luis Armadans; Ana Gonzalez Bachs
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.